Compound class:
Synthetic organic
Comment: TH-4000E is the active compound generated from the prodrug tarloxotinib (TH-4000).
|
|
Bioactivity Comments |
To date (Nov 2016) data for this drug has been published in abstract form only (Abstract 5358: The hypoxia-activated EGFR-TKI TH-4000 overcomes erlotinib-resistance in preclinical NSCLC models at plasma levels achieved in a Phase 1 clinical trial and Abstract e13548: TH-4000, a hypoxia-activated EGFR/Her2 inhibitor to treat EGFR-TKI resistant T790M-negative NSCLC. We await publication in a peer reviewed article. |